MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-27-2024
Ampio Pharmaceuticals Operating Income 2011-2026 | AMPE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | -33.3 M | -39.1 M | -24 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24 M | -39.1 M | -32.1 M |
Quarterly Operating Income Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.67 M | - | - | - | -9.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.67 M | -9.5 M | -8.58 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 28.91 | 4.94 % | $ 1.4 B |  USA |
 |
Amarin Corporation plc
AMRN
|
-67.6 M | $ 15.03 | 1.14 % | $ 6.13 B |  Irlanda |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
argenx SE
ARGX
|
-349 M | $ 836.13 | 0.31 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-51.4 M | $ 4.14 | 5.61 % | $ 353 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Adagene
ADAG
|
-36 M | $ 3.18 | 11.58 % | $ 179 M |  China |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biogen
BIIB
|
7.04 B | $ 198.18 | 1.37 % | $ 29 B | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 106.92 | 1.1 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 217.6 | -0.23 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30 M | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
137 M | $ 40.32 | 5.15 % | $ 4.16 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 53.56 | 9.46 % | $ 4.82 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.41 | 2.32 % | $ 360 M | Britain |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.35 | 0.54 % | $ 1.51 B | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
249 M | $ 14.93 | 2.02 % | $ 4.61 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |